US 11,987,605 B2
Mutant MYC fusion polypeptides and uses thereof
Taylor Gill, Cambridge, MA (US); Hannu Rajaniemi, Corte Madera, CA (US); and Nikolai Eroshenko, Boston, MA (US)
Assigned to Helix Nanotechnologies Inc, Boston, MA (US)
Filed by Helix Nanotechnologies Inc, Boston, MA (US)
Filed on Sep. 18, 2020, as Appl. No. 17/025,717.
Claims priority of provisional application 62/902,526, filed on Sep. 19, 2019.
Prior Publication US 2021/0107955 A1, Apr. 15, 2021
Int. Cl. C07K 14/47 (2006.01); C12N 5/10 (2006.01); C12N 5/16 (2006.01); C12N 15/63 (2006.01)
CPC C07K 14/4703 (2013.01) [C12N 5/10 (2013.01); C12N 5/16 (2013.01); C12N 15/63 (2013.01); C07K 2319/09 (2013.01); C07K 2319/70 (2013.01); C12N 2330/50 (2013.01)] 21 Claims
 
1. A fusion polypeptide comprising a mutant dominant negative MYC polypeptide and a repressor domain, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO: 29.